ノロウイルスワクチン:世界の市場機会分析・予測

【英語タイトル】MarketVIEW: Norovirus vaccines - Global vaccine commercial opportunity assessment

VacZine Analyticsが出版した調査資料(VAZ2006002)・商品コード:VAZ2006002
・発行会社(調査会社):VacZine Analytics
・発行日:2020年6月
・ページ数:n/a
・レポート言語:英語
・レポート形式:Executive presentation (~200 slides.pdf) + 2 x MS-Excel forecast model(s) (.xls)
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Region PriceUSD10,995 ⇒換算¥1,176,465見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Noroviruses (NoVs) called “Norwalk-like viruses” are a group of single-stranded positive sense RNA viruses and members of the family Caliciviridae. Noroviruses are transmitted from human-to-human (fecal-oral) and via food sources. They are one of the most highly infectious viruses known. In the community, NVs most commonly cause a self-limiting mild disease of short duration with gastrointestinal symptoms, usually resolving after 1 to 3 days. However, in infants, elderly and immunocompromised persons dehydration occurs requiring medical attention and/or hospital admission for the administration of IV fluids.
Globally, norovirus is associated with approximately one-fifth of all diarrhea cases, with similar prevalence in both children and adults. It is the 2nd most common cause of death in children <5 yrs and the most common cause of diarrheal death in children >5 yrs with similar patterns across WHO regions. In developing countries, norovirus is estimated to cause over 200,000 deaths annually and around 700 million illnesses. NoV outbreaks are also a well-known issue in confined environments such as long-term care facilities, hospitals, military installations and commercial cruise ship liners. In these cases, the virus can cause severe disruption and economic loss.

Because of the success of the rotavirus vaccine reducing disease burden, it is hoped a new norovirus vaccine can have a similar impact, now that the virus has taken a more prominent role. However, the SARS-CoV-2 pandemic (2020) will impact upon the norovirus vaccine timeframe and proposition. The two main programs operated by Takeda Pharmaceuticals and Vaxart were in clinical stages of testing and we await further status updates. Chinese developers are pressing ahead.

This MarketVIEW product is a comprehensive Executive presentation + MS Excel-based model(s), which forecasts the potential commercial value of Norovirus vaccines across 113 major Western and emerging markets and GAVI to 2035*. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates for all major market segments. There is a thorough review of global epidemiology, economic burden, competitive vaccine landscape. Brand new model scenarios explore segment prioritization (post-COVID-19), vaccine duration of immunity and various new adjustments. This product is ideally suited to those organisations wanting an extended, up-to-date global forecast for this vaccine opportunity.

THIS PRODUCT IS A EXECUTIVE PRESENTATION (>200 slides, .pdf) + scenario MODEL(s)

【レポートの目次】

PRODUCT CONTENTS:
Published June 2020 (CAT No: VAMV015)
****This product is a summary presentation (.pdf), a forecast model (.xls)
Contents – Summary presentation (.pdf)2
Contents
Author’s notes
Executive summary
[SECTION 1] Norovirus vaccines: key commercial model outputs
[SECTION 2] Norovirus: virus and disease background
[SECTION 3] Norovirus: global epidemiology – outbreak and incidence data
[SECTION 4] Norovirus: US epidemiology – outbreak and incidence data
[SECTION 5] Norovirus: EU epidemiology – outbreak and incidence data
[SECTION 6] Norovirus: ROW epidemiology – outbreak and incidence data
[SECTION 7] Norovirus: Epidemiology – focus on pediatrics/hospitalization
[SECTION 8] Norovirus: Epidemiology – focus on elderly and “at risk”/hospitalization
[SECTION 9] Norovirus: Epidemiology – focus on other groups
[SECTION 10] Norovirus vaccines: background and rationale
[SECTION 11] Norovirus vaccines: R&D pipeline
[SECTION 12] Norovirus vaccines modelling commercial potential
Bibliography
About VacZine Analytics
Disclaimer
PAGES: ~200 slides fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand models x 2 (MS Excel-based)
Worksheets = >70 interconnected



★調査レポート[ノロウイルスワクチン:世界の市場機会分析・予測] (コード:VAZ2006002)販売に関する免責事項を必ずご確認ください。
★調査レポート[ノロウイルスワクチン:世界の市場機会分析・予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆